Not logged in
  Home   Markets   Shares   Funds   Portfolio   Toolbox   Charting   Alerts   Directory   
 Admin   

Fri 10 Dec 2010, 16:55 AIP - Adcock Ingram Holdings - Update on The MCC resolution to withdraw
AIP
AIP                                                                             
AIP - Adcock Ingram Holdings - Update on The MCC resolution to withdraw         
Dextropropoxyphene - Containing medicines from The South African Market         
ADCOCK INGRAM HOLDINGS LIMITED                                                  
(Registration number 2007/016236/06)                                            
(Incorporated in the Republic of South Africa)                                  
Share code: AIP      ISIN: ZAE000123436                                         
("Adcock Ingram" or "the Company")                                              
UPDATE ON THE MCC RESOLUTION TO WITHDRAW DEXTROPROPOXYPHENE-CONTAINING MEDICINES
FROM THE SOUTH AFRICAN MARKET                                                   
Further to the announcement released earlier today on SENS, Adcock Ingram would 
like to advise that the Company has received notification from the Medicines    
Control Council of the Department of Health ("MCC") relating to the withdrawal  
of dextropropoxyphene ("DPP") containing medicines from the South African       
market.                                                                         
The notification confirms that the MCC has resolved that:                       
all DPP containing medicines be withdrawn from the market;                      
no new prescriptions of DPP containing medicines be allowed with immediate      
effect; and                                                                     
a three-month change-over period be permitted for patients who cannot be        
switched immediately to an alternate therapy.                                   
Adcock Ingram has suspended all promotion and sales of DPP containing products  
pending further interaction with the MCC. Adcock Ingram will work with the MCC  
to formulate and execute a plan going forward to ensure continued safety of     
South African patients.                                                         
For media queries please contact:                                               
Brunswick                                                                       
Marina Bidoli or Nthabiseng Mofokeng                                            
+27 11 502 7300                                                                 
All external queries can be emailed to synapforte@adcock.com                    
Midrand                                                                         
10 December 2010                                                                
Sponsor                                                                         
Deutsche Securities (SA) (Proprietary) Limited                                  
Date: 10/12/2010 16:55:08 Produced by the JSE SENS Department.                  
The SENS service is an information dissemination service administered by the    
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or            
implicitly, represent, warrant or in any way guarantee the truth, accuracy or   
completeness of the information published on SENS. The JSE, their officers,     
employees and agents accept no liability for (or in respect of) any direct,     
indirect, incidental or consequential loss or damage of any kind or nature,     
howsoever arising, from the use of SENS or the use of, or reliance on,          
information disseminated through SENS.
Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
Other Profile Group sites: FundsData Online (unit trust data)  |  Profile Group corporate site
Terms of Use |  Privacy Policy |  PAIA manual |  FAQs/Help |  Site Map |  © Copyright Reserved 2026  ]
  


Powered by ProfileData

Profile Mobile App Google Play Store Apple App Store


Follow us on: